1.88
+0.33(+21.29%)
Currency In USD
| Previous Close | 1.55 |
| Open | 1.64 |
| Day High | 1.95 |
| Day Low | 1.59 |
| 52-Week High | 3.95 |
| 52-Week Low | 0.69 |
| Volume | 3.11M |
| Average Volume | 2.29M |
| Market Cap | 90.06M |
| PE | -1.55 |
| EPS | -1.21 |
| Moving Average 50 Days | 0.91 |
| Moving Average 200 Days | 1.06 |
| Change | 0.33 |
If you invested $1000 in Shattuck Labs, Inc. (STTK) since IPO date, it would be worth $97.16 as of September 09, 2025 at a share price of $1.88. Whereas If you bought $1000 worth of Shattuck Labs, Inc. (STTK) shares 3 years ago, it would be worth $585.67 as of September 09, 2025 at a share price of $1.88.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors
GlobeNewswire Inc.
Aug 26, 2025 10:30 AM GMT
— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma cash and cash equivalents, assumi
Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease
GlobeNewswire Inc.
Aug 21, 2025 2:17 PM GMT
– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases – – The Company is on track to dose the first participant in it
Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million
GlobeNewswire Inc.
Aug 05, 2025 10:30 AM GMT
– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease – – Pro forma cash and cash equivalents from aggregate proceeds antici